menu
    • menu
    [{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Series B Financing","leadProduct":"PS-002","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Purespring Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"7","companyTruncated":"Purespring Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"PS-002","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Purespring Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"SwanBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ SwanBio Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Purespring Therapeutics \/ SwanBio Therapeutics"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Purespring Therapeutics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"PS-002","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Purespring Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Purespring Therapeutics

    Menu

    Purespring Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PS-002 for the Treatment of IgA Nephropathy in Adults

                            Details : PS-002 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Glomerulonephritis, IGA.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 19, 2025

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Purespring Wins EMA Orphan Drug Status for PS-002 in IgA Nephropathy

                            Details : PS-002 is a Purespring’s lead cell and gene therapy programme, currently being investigated in patients with IgA nephropathy (IgAN).

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 28, 2025

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Purespring Therapeutics Raises $105M to Transform Kidney Disease Treatment

                            Details : The proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial of PS-002 for IgAN, a chronic kidney disease primarily affecting young adults.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 09, 2024

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Charles River Laboratories, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration

                            Details : Purespring’s Adeno Associated Virus (AAV) based gene therapy presents a lower-dose, local delivery approach which maximizes both safety and efficacy, as well as lowering the cost of goods.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 15, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Charles River Laboratories, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : SwanBio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Purespring Therapeutics And SwanBio Therapeutics Announce Licensing Agreement for Use of FunSel Screening Plat...

                            Details : Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have an option to develop any targets identified and to own and commercialise any ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 18, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : SwanBio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth